Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MITOTANE

All products: general benefit

Other products in the same Health Canada class (L01X, L01XX) — coverage varies; not interchangeable

  • Altretamine (Hexalen): general benefit
  • Hydroxyurea (Hydrea): general benefit
  • Procarbazine (Matulane): general benefit

Lysodren · DIN 00463221 · 500mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Lysodren · DIN 00463221 Manufacturer: HRA Pharma Rare Diseases; listing date 2021-11-30 Health Canada: Marketed since 2025-06-26 · brand LYSODREN · ATC L01XX23 MITOTANE · form Tablet · route Oral · ingredients MITOTANE 500 MG · company Esteve pharmaceuticals s.a. · schedule Prescription
Check this DIN again · Health Canada product record

Lysodren: Formulary list price $9.7900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.7900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3348 · Verify on the e-Formulary ↗ (DIN 00463221)

Source record
DIN 00463221: Lysodren Raw flags: sec3=Y Item: 100000086; group id 176; item number 0318; lccId None; manufacturer id HRA Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $9.7900; ministry $9.7900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00463221 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3348
Shortage status: resolved shortage (ended 2019-01-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00463221
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

HYDROXYUREA

· 3 products · General benefit · strengths: 500mg · Cap

PROCARBAZINE HCL

· 1 products · General benefit · strengths: 50mg · Cap

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab

CYPROTERONE ACETATE

· 4 products · General benefit · strengths: 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications LYSODREN® (mitotane tablets) is indicated for: • The treatment of inoperable adrenocortical carcinoma of both functional and non-functional type. 1.1. Pediatrics (<18 years of age) Based on the data submitted and reviewed by Health Canada, the safety and efficacy of LYSODREN in patients <18 years of age have not been established; therefore, Health Canada has not authorized an indication for pediatric use. Neuropsychological impairment has been reported in children and adolescents receiving LYSODREN therapy (see 7. Warnings and Precautions, Neurologic section). 1.2. Geriatrics No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00084888.PDF PM date: December 31, 1979 Source product: LYSODREN; DIN 00463221; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.